董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nancy L. Snyderman | 女 | Director | 72 | 51.31万美元 | 未持股 | 2025-09-15 |
| Richard B. Gaynor | 男 | Director | 75 | 49.46万美元 | 未持股 | 2025-09-15 |
| Cato T. Laurencin | 男 | Director | 66 | 未披露 | 未持股 | 2025-09-15 |
| Nancy S. Lurker | 女 | Director | 67 | 未披露 | 未持股 | 2025-09-15 |
| Andy Wilson | 男 | Director | 66 | 未披露 | 未持股 | 2025-09-15 |
| Christopher I. Wright | 男 | Director | 59 | 未披露 | 未持股 | 2025-09-15 |
| Richard F. Pops | 男 | Chairman and Chief Executive Officer | 63 | 804.17万美元 | 未持股 | 2025-09-15 |
| Brian P. McKeon | 男 | Director | 63 | 0.42万美元 | 未持股 | 2025-09-15 |
| Nancy S. Lurker | 女 | Director | 67 | 未披露 | 未持股 | 2025-09-15 |
| Shane Cooke | 男 | Director | 63 | 48.81万美元 | 未持股 | 2025-09-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David J. Gaffin | 男 | Executive Vice President, Secretary,Chief Legal Officer and Chief Compliance Officer | 53 | 289.01万美元 | 未持股 | 2025-09-15 |
| Joshua Reed | 男 | Senior Vice President and Chief Financial Officer | 52 | 未披露 | 未持股 | 2025-09-15 |
| Craig C. Hopkinson | 男 | Executive Vice President, Research and Development and Chief Medical Officer | 57 | 395.71万美元 | 未持股 | 2025-09-15 |
| Blair C. Jackson | 男 | Executive Vice President,Chief Operating Officer,Interim Principal Accounting Officer and Chief Risk Officer | 52 | 未披露 | 未持股 | 2025-09-15 |
| C. Todd Nichols | 男 | Senior Vice President and Chief Commercial Officer | 56 | 未披露 | 未持股 | 2025-09-15 |
| Richard F. Pops | 男 | Chairman and Chief Executive Officer | 63 | 804.17万美元 | 未持股 | 2025-09-15 |
董事简历
中英对照 | 中文 | 英文- Nancy L. Snyderman
-
NancyL.Snyderman是一名委员会认证的耳鼻喉科医生，目前是斯坦福大学全球健康创新中心的咨询教授。她曾担任NBC News的首席医学编辑（2006年至2015年），也曾担任宾夕法尼亚大学（the University of Pennsylvania）的耳鼻喉科临床教授（2003年8月至2015年12月）。从2003年1月到2006年9月，Snyderman博士在强生公司公司（一家公开上市的制药公司）担任公司通讯高级副总裁。她从1994年7月到2003年6月在California Pacific Medical Center担任耳鼻喉科医生，从1987年到2003年5月担任ABC News医学编辑。Snyderman博士是美国外科医学院（American College of Surgeons）的研究员。她目前担任GE&；8217；S HealthyMagination、梦百合改善研究所、韦尔斯利学院奥尔布赖特研究所、匹兹堡大学医学中心眼耳基金会和国家脑膜炎基金会的董事。在Snyderman博士担任美国全国广播公司（NBC）和美国广播公司（ABC）医学记者期间，她获得了艾美奖，爱德华·R·莫罗奖，哥伦比亚大学杜邦奖和格雷西奖。Snyderman博士在内布拉斯加大学（University of Nebraska）的医学院就读，并在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻喉科住院医师。
Nancy L. Snyderman,is an oncologic surgeon and clinical researcher. She was a consulting professor at Stanford University Center for Innovation in Global Health from July 2019 to July 2022, served as Chief Medical Editor at NBC News from 2006 until 2015 and was a clinical professor of Otolaryngology at the University of Pennsylvania from August 2003 to December 2015. Dr. Snyderman was Senior Vice President Corporate Communications at Johnson & Johnson, a publicly-traded pharmaceutical company, from January 2003 to September 2006. She practiced as an Otolaryngologist at UC San Francisco and the California Pacific Medical Center from July 1994 to June 2003 and acted as Medical Editor for ABC News from 1987 until May 2003. Dr. Snyderman previously served on the board of directors of Future Health ESG Corp., a publicly-traded special purpose acquisition company, from September 2021 to March 2024 and Axonics, Inc., a publicly-traded medical device company, from April 2019 to November 2024. Dr. Snyderman is a Kellogg Fellow, a Fellow in the American College of Surgeons and co-founder of the Stanford University-NBC News Global Media Fellowship. During Dr. Snyderman's tenure as a medical journalist at NBC News and ABC News, she received Emmy Awards, Edward R. Murrow Awards, a Columbia University DuPont Award, and a Gracie Award for her reporting. Dr. Snyderman attended medical school at the University of Nebraska and completed residencies in Pediatrics and Otolaryngology at the University of Pittsburgh. - NancyL.Snyderman是一名委员会认证的耳鼻喉科医生，目前是斯坦福大学全球健康创新中心的咨询教授。她曾担任NBC News的首席医学编辑（2006年至2015年），也曾担任宾夕法尼亚大学（the University of Pennsylvania）的耳鼻喉科临床教授（2003年8月至2015年12月）。从2003年1月到2006年9月，Snyderman博士在强生公司公司（一家公开上市的制药公司）担任公司通讯高级副总裁。她从1994年7月到2003年6月在California Pacific Medical Center担任耳鼻喉科医生，从1987年到2003年5月担任ABC News医学编辑。Snyderman博士是美国外科医学院（American College of Surgeons）的研究员。她目前担任GE&；8217；S HealthyMagination、梦百合改善研究所、韦尔斯利学院奥尔布赖特研究所、匹兹堡大学医学中心眼耳基金会和国家脑膜炎基金会的董事。在Snyderman博士担任美国全国广播公司（NBC）和美国广播公司（ABC）医学记者期间，她获得了艾美奖，爱德华·R·莫罗奖，哥伦比亚大学杜邦奖和格雷西奖。Snyderman博士在内布拉斯加大学（University of Nebraska）的医学院就读，并在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻喉科住院医师。
- Nancy L. Snyderman,is an oncologic surgeon and clinical researcher. She was a consulting professor at Stanford University Center for Innovation in Global Health from July 2019 to July 2022, served as Chief Medical Editor at NBC News from 2006 until 2015 and was a clinical professor of Otolaryngology at the University of Pennsylvania from August 2003 to December 2015. Dr. Snyderman was Senior Vice President Corporate Communications at Johnson & Johnson, a publicly-traded pharmaceutical company, from January 2003 to September 2006. She practiced as an Otolaryngologist at UC San Francisco and the California Pacific Medical Center from July 1994 to June 2003 and acted as Medical Editor for ABC News from 1987 until May 2003. Dr. Snyderman previously served on the board of directors of Future Health ESG Corp., a publicly-traded special purpose acquisition company, from September 2021 to March 2024 and Axonics, Inc., a publicly-traded medical device company, from April 2019 to November 2024. Dr. Snyderman is a Kellogg Fellow, a Fellow in the American College of Surgeons and co-founder of the Stanford University-NBC News Global Media Fellowship. During Dr. Snyderman's tenure as a medical journalist at NBC News and ABC News, she received Emmy Awards, Edward R. Murrow Awards, a Columbia University DuPont Award, and a Gracie Award for her reporting. Dr. Snyderman attended medical school at the University of Nebraska and completed residencies in Pediatrics and Otolaryngology at the University of Pittsburgh.
- Richard B. Gaynor
-
Richard B. Gaynor，他是BioNTech US Inc.（前身为Neon Therapeutics, Inc.）的总裁兼研发主管（2020年5月至今），此前他于2016年11月至2020年5月在Neon Therapeutics担任该职位；Infinity Pharmaceuticals, Inc.的董事会成员（2020年3月至今）；Alkermes plc的董事会成员（2019年9月至今）；Eli Lilly and Company的各种高级临床开发和医疗事务职位（2002-2016）。包括临床发展和医疗事务高级副总裁；加州大学洛杉矶分校医学院教授（1982-1991）和Texas Southwestern Medical School教授（1991-2002），包括血液学肿瘤学主任和Simmons Cancer Center主任；近150篇出版物的作者和众多咨询委员会和委员会的参与者。包括目前担任Damon Runyon癌症研究基金会的董事，以及美国癌症研究协会和其他癌症组织的几个委员会的董事从Texas Southwestern Medical School毕业，在那里他担任内科住院医师；在加州大学洛杉矶分校医学院接受血液肿瘤学奖学金培训。于2021年12月担任再鼎医药有限公司独立董事。
Richard B. Gaynor,has served as President, Chief of Research and Development at BioNTech US Inc. (f/k/a Neon Therapeutics, Inc. ("Neon")), a wholly-owned subsidiary of BioNTech SE focused on the development of novel neoantigen-targeted T cell therapies. Dr. Gaynor had previously served as President of Research and Development at Neon since November 2016. Prior to joining Neon, Dr. Gaynor held roles in clinical development and medical affairs at Eli Lilly and Company ("Lilly") from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with General Electric, AstraZeneca, Merck and Bristol-Myers Squibb Company. Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine, followed by 11 years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at UCLA School of Medicine. Dr. Gaynor is on the editorial board of several scientific journals and has published extensively, including over 140 scientific articles. He previously served on the board of directors of Infinity Pharmaceuticals, Inc., a formerly publicly-traded biotechnology company, from March 2020 to March 2024. He currently serves on the board of directors of the Damon Runyon Cancer Research Foundation, the scientific advisory committee of Stand Up to Cancer and the finance committee of the American Association of Cancer Research, each a not-for-profit organization. Dr. Gaynor is a licensed physician with board certifications in oncology and hematology. - Richard B. Gaynor，他是BioNTech US Inc.（前身为Neon Therapeutics, Inc.）的总裁兼研发主管（2020年5月至今），此前他于2016年11月至2020年5月在Neon Therapeutics担任该职位；Infinity Pharmaceuticals, Inc.的董事会成员（2020年3月至今）；Alkermes plc的董事会成员（2019年9月至今）；Eli Lilly and Company的各种高级临床开发和医疗事务职位（2002-2016）。包括临床发展和医疗事务高级副总裁；加州大学洛杉矶分校医学院教授（1982-1991）和Texas Southwestern Medical School教授（1991-2002），包括血液学肿瘤学主任和Simmons Cancer Center主任；近150篇出版物的作者和众多咨询委员会和委员会的参与者。包括目前担任Damon Runyon癌症研究基金会的董事，以及美国癌症研究协会和其他癌症组织的几个委员会的董事从Texas Southwestern Medical School毕业，在那里他担任内科住院医师；在加州大学洛杉矶分校医学院接受血液肿瘤学奖学金培训。于2021年12月担任再鼎医药有限公司独立董事。
- Richard B. Gaynor,has served as President, Chief of Research and Development at BioNTech US Inc. (f/k/a Neon Therapeutics, Inc. ("Neon")), a wholly-owned subsidiary of BioNTech SE focused on the development of novel neoantigen-targeted T cell therapies. Dr. Gaynor had previously served as President of Research and Development at Neon since November 2016. Prior to joining Neon, Dr. Gaynor held roles in clinical development and medical affairs at Eli Lilly and Company ("Lilly") from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with General Electric, AstraZeneca, Merck and Bristol-Myers Squibb Company. Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine, followed by 11 years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at UCLA School of Medicine. Dr. Gaynor is on the editorial board of several scientific journals and has published extensively, including over 140 scientific articles. He previously served on the board of directors of Infinity Pharmaceuticals, Inc., a formerly publicly-traded biotechnology company, from March 2020 to March 2024. He currently serves on the board of directors of the Damon Runyon Cancer Research Foundation, the scientific advisory committee of Stand Up to Cancer and the finance committee of the American Association of Cancer Research, each a not-for-profit organization. Dr. Gaynor is a licensed physician with board certifications in oncology and hematology.
- Cato T. Laurencin
-
Cato T. Laurencin，现任康涅狄格大学阿尔伯特和威尔达·范杜森杰出捐赠骨科外科教授，也是该校两位指定的大学教授之一。他还是一位材料科学家和工程师，是康涅狄格大学材料科学和工程教授、化学和生物分子工程教授和生物医学工程教授。自2008年以来，他一直是康涅狄格大学的教授。他是康涅狄格州融合翻译再生工程研究所的首席执行官。此前，他曾担任康涅狄格大学健康中心卫生事务副总裁和康涅狄格大学医学院院长。从2003年到2008年，Laurencin博士是弗吉尼亚大学Lillian T. Pratt特聘教授和骨科外科主任。劳伦辛博士还被弗吉尼亚大学校长指定为大学教授。在2003年之前，Laurencin博士在德雷塞尔大学担任过多个职位，包括Helen I. Moorehead化学工程学特聘教授、骨科外科副主席和肩部外科主任，以及在MCP-Hahnemann医学院担任骨科外科临床教授和药理学和生理学研究教授。作为生物材料科学与工程国际研究员，他获得了生物材料学会的创始人奖。他是美国国家医学院、国家工程院、国家科学院的当选成员，美国艺术和科学院的当选研究员和国家发明家学会的研究员。劳伦辛博士是美国国家技术与创新奖章的获得者，Mimedx Group公司是国家技术成就的最高荣誉。他拥有500多项出版物和专利。Laurencin博士在普林斯顿大学获得工程学学士学位，在麻省理工学院获得生化工程和生物技术博士学位，在哈佛医学院获得医学博士学位，并以优异成绩毕业。
Cato T. Laurencin,currently serves as the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated University Professors at the school. He is also a materials scientist and engineer and is Professor of Materials Science and Engineering, Professor of Chemical and Biomolecular Engineering, and Professor of Biomedical Engineering at the University of Connecticut. He has been a professor at the University of Connecticut since 2008. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering. Previously, he served as Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the University of Connecticut School of Medicine. From 2003 until 2008, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and Chair of the Department of Orthopedic Surgery at the University of Virginia. Dr. Laurencin was also designated a University Professor by the President of the University of Virginia. Prior to 2003, Dr. Laurencin held various positions of increasing responsibility at Drexel University, including the Helen I. Moorehead Distinguished Professor of Chemical Engineering, Vice Chairman of the Department of Orthopedic Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopedic Surgery, and Research Professor of Pharmacology and Physiology. An International Fellow in Biomaterials Science and Engineering, he received the Founders Award from the Society for Biomaterials. He is an elected member of the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences, an elected fellow of the American Academy of Arts and Sciences and a fellow of the National Academy of Inventors. Dr. Laurencin is the recipient of the National Medal of Technology and Innovation, Mimedx Group, Inc. nation's highest honor for technological achievement. He has over 500 publications and patents. Dr. Laurencin received his B.S.E. degree in engineering from Princeton University, his Ph.D. in biochemical engineering and biotechnology from the Massachusetts Institute of Technology, and his M.D. from the Harvard Medical School where he graduated Magna Cum Laude. - Cato T. Laurencin，现任康涅狄格大学阿尔伯特和威尔达·范杜森杰出捐赠骨科外科教授，也是该校两位指定的大学教授之一。他还是一位材料科学家和工程师，是康涅狄格大学材料科学和工程教授、化学和生物分子工程教授和生物医学工程教授。自2008年以来，他一直是康涅狄格大学的教授。他是康涅狄格州融合翻译再生工程研究所的首席执行官。此前，他曾担任康涅狄格大学健康中心卫生事务副总裁和康涅狄格大学医学院院长。从2003年到2008年，Laurencin博士是弗吉尼亚大学Lillian T. Pratt特聘教授和骨科外科主任。劳伦辛博士还被弗吉尼亚大学校长指定为大学教授。在2003年之前，Laurencin博士在德雷塞尔大学担任过多个职位，包括Helen I. Moorehead化学工程学特聘教授、骨科外科副主席和肩部外科主任，以及在MCP-Hahnemann医学院担任骨科外科临床教授和药理学和生理学研究教授。作为生物材料科学与工程国际研究员，他获得了生物材料学会的创始人奖。他是美国国家医学院、国家工程院、国家科学院的当选成员，美国艺术和科学院的当选研究员和国家发明家学会的研究员。劳伦辛博士是美国国家技术与创新奖章的获得者，Mimedx Group公司是国家技术成就的最高荣誉。他拥有500多项出版物和专利。Laurencin博士在普林斯顿大学获得工程学学士学位，在麻省理工学院获得生化工程和生物技术博士学位，在哈佛医学院获得医学博士学位，并以优异成绩毕业。
- Cato T. Laurencin,currently serves as the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated University Professors at the school. He is also a materials scientist and engineer and is Professor of Materials Science and Engineering, Professor of Chemical and Biomolecular Engineering, and Professor of Biomedical Engineering at the University of Connecticut. He has been a professor at the University of Connecticut since 2008. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering. Previously, he served as Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the University of Connecticut School of Medicine. From 2003 until 2008, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and Chair of the Department of Orthopedic Surgery at the University of Virginia. Dr. Laurencin was also designated a University Professor by the President of the University of Virginia. Prior to 2003, Dr. Laurencin held various positions of increasing responsibility at Drexel University, including the Helen I. Moorehead Distinguished Professor of Chemical Engineering, Vice Chairman of the Department of Orthopedic Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopedic Surgery, and Research Professor of Pharmacology and Physiology. An International Fellow in Biomaterials Science and Engineering, he received the Founders Award from the Society for Biomaterials. He is an elected member of the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences, an elected fellow of the American Academy of Arts and Sciences and a fellow of the National Academy of Inventors. Dr. Laurencin is the recipient of the National Medal of Technology and Innovation, Mimedx Group, Inc. nation's highest honor for technological achievement. He has over 500 publications and patents. Dr. Laurencin received his B.S.E. degree in engineering from Princeton University, his Ph.D. in biochemical engineering and biotechnology from the Massachusetts Institute of Technology, and his M.D. from the Harvard Medical School where he graduated Magna Cum Laude.
- Nancy S. Lurker
-
Nancy S. Lurker，最近于2016年9月至2023年7月担任EyePoint Pharmaceuticals，Inc.（“EyePoint”）的首席执行官，该公司是一家上市的专业生物制药公司，此时她过渡到目前担任EyePoint董事会副主席的角色。她还曾于2016年9月至2023年1月担任EYEPoint总裁。在此之前，她曾于2008年至2015年担任PDI，Inc.（一家上市的医疗保健商业化公司（现为Interpace诊断集团有限公司）的总裁兼首席执行官，并于2006年至2007年担任诺华制药公司的高级副总裁兼首席营销官。在此之前，Lurker女士曾在领先的制药公司担任过各种高管和其他高级职务，包括私人持股的医疗保健信息公司ImpactRx，Inc.、Pharmacia Corporation（现为辉瑞，Inc.的一部分）以及百时美施贵宝公司。除了EyePoint和Collegium制药公司外，Lurker女士目前还担任私人合同研究机构Altasciences，LLC和致力于通过质量标准改善人类健康的非营利组织国家卫生基金会的董事会成员。Lurker女士此前曾在上市的专业制药公司Aquestive Therapeutics, Inc.、2018年至2022年4月的美国癌症治疗中心、2016年至2020年的美国癌症治疗中心以及2004年至2018年的不同时间的董事会任职，目前和以前的上市公司Auxilium Pharmaceuticals, Inc.、X4 Pharmaceuticals, Inc.TERM4 Pharmaceuticals，Inc.、万灵科 plc、PDI，Inc.、Elan Corporation，plc和ConjuChem Biotechnologies的董事会成员。Lurker女士获得了西雅图太平洋大学的生物学学士学位和埃文斯维尔大学的工商管理硕士学位。
Nancy S. Lurker,most recently served as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. ("EyePoint"), a publicly-traded specialty biopharmaceutical company, from September 2016 to July 2023, at which time she transitioned to her current role as Vice-Chair of EyePoint's board of directors. She also served as President of EyePoint from September 2016 to January 2023. Prior to that, she served as President and Chief Executive Officer of PDI, Inc., a publicly-traded healthcare commercialization company (now Interpace Diagnostics Group, Inc.), from 2008 to 2015 and as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation from 2006 to 2007. Prior to that, Ms. Lurker held various executive and other senior roles at leading pharmaceutical companies, including ImpactRx, Inc., a privately held healthcare information company, Pharmacia Corporation (now a part of Pfizer, Inc.), and Bristol-Myers Squibb Company. In addition to EyePoint and Collegium Pharmaceutical, Inc., Ms. Lurker currently serves on the boards of directors of Altasciences, LLC, a private contract research organization, and National Sanitation Foundation, a not-for-profit organization dedicated to improving human health through quality standards. Ms. Lurker previously served on the boards of directors of Aquestive Therapeutics, Inc., a publicly-traded specialty pharmaceutical company, from 2018 to April 2022, the Cancer Treatment Centers of America from 2016 to 2020 and, at various times from 2004 to 2018, current and formerly publicly-traded companies Auxilium Pharmaceuticals, Inc., X4 Pharmaceuticals, Inc., Mallinckrodt plc, PDI, Inc., Elan Corporation, plc and ConjuChem Biotechnologies. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. - Nancy S. Lurker，最近于2016年9月至2023年7月担任EyePoint Pharmaceuticals，Inc.（“EyePoint”）的首席执行官，该公司是一家上市的专业生物制药公司，此时她过渡到目前担任EyePoint董事会副主席的角色。她还曾于2016年9月至2023年1月担任EYEPoint总裁。在此之前，她曾于2008年至2015年担任PDI，Inc.（一家上市的医疗保健商业化公司（现为Interpace诊断集团有限公司）的总裁兼首席执行官，并于2006年至2007年担任诺华制药公司的高级副总裁兼首席营销官。在此之前，Lurker女士曾在领先的制药公司担任过各种高管和其他高级职务，包括私人持股的医疗保健信息公司ImpactRx，Inc.、Pharmacia Corporation（现为辉瑞，Inc.的一部分）以及百时美施贵宝公司。除了EyePoint和Collegium制药公司外，Lurker女士目前还担任私人合同研究机构Altasciences，LLC和致力于通过质量标准改善人类健康的非营利组织国家卫生基金会的董事会成员。Lurker女士此前曾在上市的专业制药公司Aquestive Therapeutics, Inc.、2018年至2022年4月的美国癌症治疗中心、2016年至2020年的美国癌症治疗中心以及2004年至2018年的不同时间的董事会任职，目前和以前的上市公司Auxilium Pharmaceuticals, Inc.、X4 Pharmaceuticals, Inc.TERM4 Pharmaceuticals，Inc.、万灵科 plc、PDI，Inc.、Elan Corporation，plc和ConjuChem Biotechnologies的董事会成员。Lurker女士获得了西雅图太平洋大学的生物学学士学位和埃文斯维尔大学的工商管理硕士学位。
- Nancy S. Lurker,most recently served as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. ("EyePoint"), a publicly-traded specialty biopharmaceutical company, from September 2016 to July 2023, at which time she transitioned to her current role as Vice-Chair of EyePoint's board of directors. She also served as President of EyePoint from September 2016 to January 2023. Prior to that, she served as President and Chief Executive Officer of PDI, Inc., a publicly-traded healthcare commercialization company (now Interpace Diagnostics Group, Inc.), from 2008 to 2015 and as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation from 2006 to 2007. Prior to that, Ms. Lurker held various executive and other senior roles at leading pharmaceutical companies, including ImpactRx, Inc., a privately held healthcare information company, Pharmacia Corporation (now a part of Pfizer, Inc.), and Bristol-Myers Squibb Company. In addition to EyePoint and Collegium Pharmaceutical, Inc., Ms. Lurker currently serves on the boards of directors of Altasciences, LLC, a private contract research organization, and National Sanitation Foundation, a not-for-profit organization dedicated to improving human health through quality standards. Ms. Lurker previously served on the boards of directors of Aquestive Therapeutics, Inc., a publicly-traded specialty pharmaceutical company, from 2018 to April 2022, the Cancer Treatment Centers of America from 2016 to 2020 and, at various times from 2004 to 2018, current and formerly publicly-traded companies Auxilium Pharmaceuticals, Inc., X4 Pharmaceuticals, Inc., Mallinckrodt plc, PDI, Inc., Elan Corporation, plc and ConjuChem Biotechnologies. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
- Andy Wilson
-
Andy Wilson，最近于2009年至2018年担任生命科学诊断、发现和分析解决方案公司珀金埃尔默，Inc.（“珀金埃尔默”）的首席财务官和高级副总裁，负责监督该组织的增长战略。在加入珀金埃尔默之前，Wilson先生于1997年至2009年在全球科技集团丹纳赫公司担任关键的业务发展和财务职务，包括投资者关系部门的公司副总裁一职。在其职业生涯的早期，Wilson先生曾任职于AlliedSignal，Inc.（现为霍尼韦尔国际公司），曾担任商用航空电子系统部门的财务副总裁兼首席财务官。在此之前，威尔逊先生的工作包括在百事可乐公司担任越来越重要的财务和控制职位，以及在E.F. Hutton and Company和毕马威Peat Marwick担任职务。此前，他曾于2015年至2019年初担任复杂精密机电装置供应商Sparton Corporation的董事会成员，他最后一次担任该公司的董事长。Wilson先生是一名注册会计师。
Andy Wilson,most recently served as Chief Financial Officer and Senior Vice President of PerkinElmer, Inc. ("PerkinElmer"), a life sciences diagnostics, discovery and analytical solutions company, from 2009 to 2018, with responsibility for oversight of the organization's growth strategy. Prior to PerkinElmer, Mr. Wilson held key business development and finance roles at Danaher Corporation, a global science and technology conglomerate, from 1997 to 2009, including the position of Corporate Vice President of Investor Relations. Earlier in his career, Mr. Wilson worked at AlliedSignal, Inc. (now Honeywell International Inc.), where he served as Vice President of Finance and Chief Financial Officer for the Commercial Avionics Systems division. Prior to that, Mr. Wilson's work included financial and controllership positions of increasing responsibility at PepsiCo, Inc., as well as roles at E.F. Hutton and Company and KPMG Peat Marwick. He was previously a member of the board of directors of Sparton Corporation, a provider of complex and sophisticated electromechanical devices, from 2015 to early 2019, where he last served as chairman of the board. Mr. Wilson is a certified public accountant. - Andy Wilson，最近于2009年至2018年担任生命科学诊断、发现和分析解决方案公司珀金埃尔默，Inc.（“珀金埃尔默”）的首席财务官和高级副总裁，负责监督该组织的增长战略。在加入珀金埃尔默之前，Wilson先生于1997年至2009年在全球科技集团丹纳赫公司担任关键的业务发展和财务职务，包括投资者关系部门的公司副总裁一职。在其职业生涯的早期，Wilson先生曾任职于AlliedSignal，Inc.（现为霍尼韦尔国际公司），曾担任商用航空电子系统部门的财务副总裁兼首席财务官。在此之前，威尔逊先生的工作包括在百事可乐公司担任越来越重要的财务和控制职位，以及在E.F. Hutton and Company和毕马威Peat Marwick担任职务。此前，他曾于2015年至2019年初担任复杂精密机电装置供应商Sparton Corporation的董事会成员，他最后一次担任该公司的董事长。Wilson先生是一名注册会计师。
- Andy Wilson,most recently served as Chief Financial Officer and Senior Vice President of PerkinElmer, Inc. ("PerkinElmer"), a life sciences diagnostics, discovery and analytical solutions company, from 2009 to 2018, with responsibility for oversight of the organization's growth strategy. Prior to PerkinElmer, Mr. Wilson held key business development and finance roles at Danaher Corporation, a global science and technology conglomerate, from 1997 to 2009, including the position of Corporate Vice President of Investor Relations. Earlier in his career, Mr. Wilson worked at AlliedSignal, Inc. (now Honeywell International Inc.), where he served as Vice President of Finance and Chief Financial Officer for the Commercial Avionics Systems division. Prior to that, Mr. Wilson's work included financial and controllership positions of increasing responsibility at PepsiCo, Inc., as well as roles at E.F. Hutton and Company and KPMG Peat Marwick. He was previously a member of the board of directors of Sparton Corporation, a provider of complex and sophisticated electromechanical devices, from 2015 to early 2019, where he last served as chairman of the board. Mr. Wilson is a certified public accountant.
- Christopher I. Wright
-
Christopher I. Wright曾在Ring Therapeutics，Inc.（“Ring”）担任首席医疗官兼转化研究主管，该公司专注于通过其共生病毒平台彻底改变基因疗法。在加入Ring之前，Dr. Wright曾于2021年5月通过2022年12月被Solid Biosciences Inc.收购，担任AavantiBio，Inc.的高级副总裁兼首席医疗官，该公司专注于开发用于治疗使人衰弱的疾病的精准基因疗法。从2019年4月到2021年3月，Wright博士担任Cyclerion Therapeutics, Inc.（“Cyclerion”）的高级副总裁兼首席医疗官，该公司是从Ironwood Pharmaceuticals, Inc.制药公司（“Ironwood”）公开交易的分拆公司，在那里他领导了跨治疗领域的全球开发职能。2017年3月至2019年4月，Dr. Wright担任Ironwood高级副总裁、首席开发官。在此之前，Wright博士曾担任Axcella Health公司高级副总裁、首席医疗官以及Vertex Pharmaceuticals Incorporated公司全球药物开发和事务高级副总裁，领导跨治疗领域的全球开发职能。Wright博士此前是哈佛医学院神经病学副教授，曾在布莱根妇女医院担任20年的执业神经科医生。他此前曾担任Cyclerion的科学顾问。Wright博士在哈佛大学获得了生化科学学士学位，在哈佛医学院获得了医学和神经科学医学博士学位，在自由大学获得了神经解剖学博士学位，并在哈佛医学院获得了临床研究硕士学位。
Christopher I. Wright,has served as Chief Medical Officer, Head of Translational Research at Ring Therapeutics, Inc. ("Ring"), a company focused on revolutionizing gene therapy with its commensal virome platform. Prior to joining Ring, Dr. Wright served as Senior Vice President, Chief Medical Officer of AavantiBio, Inc., a company focused on development of precision gene therapies for the treatment of debilitating diseases, from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc. ("Cyclerion"), a publicly-traded spin-off from Ironwood Pharmaceuticals, Inc. ("Ironwood"), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women's Hospital for 20 years. He previously served as a Scientific Advisor for Cyclerion. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit and his MMSc. in Clinical Investigation from Harvard Medical School. - Christopher I. Wright曾在Ring Therapeutics，Inc.（“Ring”）担任首席医疗官兼转化研究主管，该公司专注于通过其共生病毒平台彻底改变基因疗法。在加入Ring之前，Dr. Wright曾于2021年5月通过2022年12月被Solid Biosciences Inc.收购，担任AavantiBio，Inc.的高级副总裁兼首席医疗官，该公司专注于开发用于治疗使人衰弱的疾病的精准基因疗法。从2019年4月到2021年3月，Wright博士担任Cyclerion Therapeutics, Inc.（“Cyclerion”）的高级副总裁兼首席医疗官，该公司是从Ironwood Pharmaceuticals, Inc.制药公司（“Ironwood”）公开交易的分拆公司，在那里他领导了跨治疗领域的全球开发职能。2017年3月至2019年4月，Dr. Wright担任Ironwood高级副总裁、首席开发官。在此之前，Wright博士曾担任Axcella Health公司高级副总裁、首席医疗官以及Vertex Pharmaceuticals Incorporated公司全球药物开发和事务高级副总裁，领导跨治疗领域的全球开发职能。Wright博士此前是哈佛医学院神经病学副教授，曾在布莱根妇女医院担任20年的执业神经科医生。他此前曾担任Cyclerion的科学顾问。Wright博士在哈佛大学获得了生化科学学士学位，在哈佛医学院获得了医学和神经科学医学博士学位，在自由大学获得了神经解剖学博士学位，并在哈佛医学院获得了临床研究硕士学位。
- Christopher I. Wright,has served as Chief Medical Officer, Head of Translational Research at Ring Therapeutics, Inc. ("Ring"), a company focused on revolutionizing gene therapy with its commensal virome platform. Prior to joining Ring, Dr. Wright served as Senior Vice President, Chief Medical Officer of AavantiBio, Inc., a company focused on development of precision gene therapies for the treatment of debilitating diseases, from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc. ("Cyclerion"), a publicly-traded spin-off from Ironwood Pharmaceuticals, Inc. ("Ironwood"), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women's Hospital for 20 years. He previously served as a Scientific Advisor for Cyclerion. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit and his MMSc. in Clinical Investigation from Harvard Medical School.
- Richard F. Pops
-
Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012. - Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
- Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012.
- Brian P. McKeon
-
Brian P. McKeon，自2025年3月起担任执行副总裁兼特别顾问。在此之前，他曾于2014年1月至2025年2月担任执行副总裁、首席财务官和财务主管，在此期间领导Idexx Laboratories，Inc.的财务和投资者关系职能。在担任IDEXX实验室公司首席财务官期间的各个时间点，McKeon先生还负责各种职能和业务领域，包括Idexx Laboratories，Inc.的企业发展、战略、全球运营和信息技术职能，以及Companion Animal Group在拉丁美洲的业务以及IDEXX实验室公司 Water、OPTI医疗以及牲畜、家禽和奶制品业务。McKeon先生自2020年12月起担任阿尔凯默斯 PLC的董事，担任财务运营委员会主席和薪酬委员会成员。McKeon先生于2003年7月至2013年12月担任IDEXX的董事，包括担任审计委员会主席和薪酬委员会成员。他还曾于2017年9月至2019年2月担任Athenahealth，Inc.的董事。McKeon先生于2007年4月至2013年12月担任铁山公司执行副总裁，并于2007年4月至2013年10月担任铁山首席财务官。McKeon先生还于2000年3月至2007年4月担任天伯伦执行副总裁兼首席财务官。从1991年到2000年，McKeon先生在百事可乐公司担任过多个财务和战略规划职位。McKeon先生拥有康涅狄格大学会计学本科学位和哈佛大学MBA学位。
Brian P. McKeon,serves as Executive Vice President and Special Advisor to IDEXX Laboratories, Inc. ("IDEXX"), a public multinational corporation providing products and services in the veterinary, livestock and poultry, dairy and water testing markets and will continue in this role until his announced retirement on June 1, 2025. He previously served as Executive Vice President, Chief Financial Officer and Treasurer of IDEXX from January 2014 to February 2025, during which time he led IDEXX's finance and investor relations functions and, from June 2019 to January 2025, oversaw IDEXX's livestock, water and human diagnostics businesses. He also served on the board of directors of IDEXX from 2003 to 2013, including as Chair of its Audit Committee and as a member of its Compensation Committee. Prior to joining IDEXX, Mr. McKeon served as Executive Vice President and Chief Financial Officer of Iron Mountain Incorporated from 2007 to 2013 and as Executive Vice President and Chief Financial Officer of The Timberland Company from 2000 to 2007. Prior to these roles, he held several finance and strategic planning positions at PepsiCo Inc., serving most recently as Vice President, Finance, at Pepsi-Cola, North America. Mr. McKeon previously served as a director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon holds a bachelor's degree in accounting from the University of Connecticut and an M.B.A with high distinction from Harvard University. - Brian P. McKeon，自2025年3月起担任执行副总裁兼特别顾问。在此之前，他曾于2014年1月至2025年2月担任执行副总裁、首席财务官和财务主管，在此期间领导Idexx Laboratories，Inc.的财务和投资者关系职能。在担任IDEXX实验室公司首席财务官期间的各个时间点，McKeon先生还负责各种职能和业务领域，包括Idexx Laboratories，Inc.的企业发展、战略、全球运营和信息技术职能，以及Companion Animal Group在拉丁美洲的业务以及IDEXX实验室公司 Water、OPTI医疗以及牲畜、家禽和奶制品业务。McKeon先生自2020年12月起担任阿尔凯默斯 PLC的董事，担任财务运营委员会主席和薪酬委员会成员。McKeon先生于2003年7月至2013年12月担任IDEXX的董事，包括担任审计委员会主席和薪酬委员会成员。他还曾于2017年9月至2019年2月担任Athenahealth，Inc.的董事。McKeon先生于2007年4月至2013年12月担任铁山公司执行副总裁，并于2007年4月至2013年10月担任铁山首席财务官。McKeon先生还于2000年3月至2007年4月担任天伯伦执行副总裁兼首席财务官。从1991年到2000年，McKeon先生在百事可乐公司担任过多个财务和战略规划职位。McKeon先生拥有康涅狄格大学会计学本科学位和哈佛大学MBA学位。
- Brian P. McKeon,serves as Executive Vice President and Special Advisor to IDEXX Laboratories, Inc. ("IDEXX"), a public multinational corporation providing products and services in the veterinary, livestock and poultry, dairy and water testing markets and will continue in this role until his announced retirement on June 1, 2025. He previously served as Executive Vice President, Chief Financial Officer and Treasurer of IDEXX from January 2014 to February 2025, during which time he led IDEXX's finance and investor relations functions and, from June 2019 to January 2025, oversaw IDEXX's livestock, water and human diagnostics businesses. He also served on the board of directors of IDEXX from 2003 to 2013, including as Chair of its Audit Committee and as a member of its Compensation Committee. Prior to joining IDEXX, Mr. McKeon served as Executive Vice President and Chief Financial Officer of Iron Mountain Incorporated from 2007 to 2013 and as Executive Vice President and Chief Financial Officer of The Timberland Company from 2000 to 2007. Prior to these roles, he held several finance and strategic planning positions at PepsiCo Inc., serving most recently as Vice President, Finance, at Pepsi-Cola, North America. Mr. McKeon previously served as a director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon holds a bachelor's degree in accounting from the University of Connecticut and an M.B.A with high distinction from Harvard University.
- Nancy S. Lurker
-
Nancy S. Lurker自2013年6月起担任董事，也是人力资源和薪酬委员会的成员。从2008年到2015年12月，她担任PDI， Inc.的董事兼首席执行官。PDI Inc.是美国领先的外包商业服务提供商，为成熟和新兴的制药、生物技术和医疗保健公司提供服务。加入PDI之前，她曾担任Novartis Pharmaceuticals Corporation的高级副总裁兼首席营销官（从2006年到2008年）。在此之前，她从2003年到2006年担任ImpactRx， Inc.的总裁兼首席执行官。从1998年到2003年，她担任Pharmacia Corporation的全球初级保健产品集团副总裁。1998年至2003年，她也是Pharmacia美国执行管理委员会的成员。Lurker女士在Bristol-Myers Squibb开始了她的职业生涯，在那里她工作了14年。Lurker女士从2011年到2015年担任Auxilium Corporation的董事，从2004年到2006年担任ConjuChem Biotechnologies， Inc.的董事，从2005年到2006年担任Elan Corporation的董事。
Nancy S. Lurker has been a director since June 2013 and is a member of Human Resources and Compensation Committee. Ms. Lurker served as a director and Chief Executive Officer of PDI, Inc. from 2008 until December 2015. PDI Inc. is a leading provider of outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the United States. Prior to joining PDI, Ms. Lurker served as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation from 2006 to 2008. Prior to that, she was President and Chief Executive Officer of ImpactRx, Inc. from 2003 to 2006. From 1998 to 2003 Ms. Lurker served as Group Vice President - Global Primary Care Products for Pharmacia Corporation. She was also a member of Pharmacia's U.S. Executive Management Committee from 1998 to 2003. Ms. Lurker began her career at Bristol-Myers Squibb, where she worked for 14 years. Ms. Lurker served as a director of Auxilium Corporation from 2011 to 2015 as a director of ConjuChem Biotechnologies, Inc. from 2004 to 2006 and as a director of Elan Corporation from 2005 to 2006. - Nancy S. Lurker自2013年6月起担任董事，也是人力资源和薪酬委员会的成员。从2008年到2015年12月，她担任PDI， Inc.的董事兼首席执行官。PDI Inc.是美国领先的外包商业服务提供商，为成熟和新兴的制药、生物技术和医疗保健公司提供服务。加入PDI之前，她曾担任Novartis Pharmaceuticals Corporation的高级副总裁兼首席营销官（从2006年到2008年）。在此之前，她从2003年到2006年担任ImpactRx， Inc.的总裁兼首席执行官。从1998年到2003年，她担任Pharmacia Corporation的全球初级保健产品集团副总裁。1998年至2003年，她也是Pharmacia美国执行管理委员会的成员。Lurker女士在Bristol-Myers Squibb开始了她的职业生涯，在那里她工作了14年。Lurker女士从2011年到2015年担任Auxilium Corporation的董事，从2004年到2006年担任ConjuChem Biotechnologies， Inc.的董事，从2005年到2006年担任Elan Corporation的董事。
- Nancy S. Lurker has been a director since June 2013 and is a member of Human Resources and Compensation Committee. Ms. Lurker served as a director and Chief Executive Officer of PDI, Inc. from 2008 until December 2015. PDI Inc. is a leading provider of outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the United States. Prior to joining PDI, Ms. Lurker served as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation from 2006 to 2008. Prior to that, she was President and Chief Executive Officer of ImpactRx, Inc. from 2003 to 2006. From 1998 to 2003 Ms. Lurker served as Group Vice President - Global Primary Care Products for Pharmacia Corporation. She was also a member of Pharmacia's U.S. Executive Management Committee from 1998 to 2003. Ms. Lurker began her career at Bristol-Myers Squibb, where she worked for 14 years. Ms. Lurker served as a director of Auxilium Corporation from 2011 to 2015 as a director of ConjuChem Biotechnologies, Inc. from 2004 to 2006 and as a director of Elan Corporation from 2005 to 2006.
- Shane Cooke
-
Shane Cooke，自2011年9月他担任公司总裁。他受雇于Alkermes 爱尔兰制药有限公司（公司的爱尔兰子公司）。从2005年5月至2011年9月16日他担任Elan公司的董事。从2007年5月至2011 年9月16日他曾任Elan公司的执行副总裁和EDT的负责人。从2001年7月加入义隆直到2011年5月，他曾任义隆电子的财务总监。在加入义隆前，他曾任彭布罗克资本有限公司（航空租赁公司）的首席执行官，而在此之前，在一些银行和航空业担任金融高级职位。他是一名注册会计师。他目前是Prothena公司（一家公开上市的生物技术公司）和Onclave（一家私人持有的公司）的董事。
Shane Cooke,served as President and as President of Alkermes Pharma Ireland Limited ("APIL"), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc ("Elan") and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. Mr. Cooke previously served on the board of directors of then publicly-traded healthcare companies UDG Healthcare plc from February 2019 to August 2021 and Endo International plc from July 2014 to April 2024. He is a chartered accountant. - Shane Cooke，自2011年9月他担任公司总裁。他受雇于Alkermes 爱尔兰制药有限公司（公司的爱尔兰子公司）。从2005年5月至2011年9月16日他担任Elan公司的董事。从2007年5月至2011 年9月16日他曾任Elan公司的执行副总裁和EDT的负责人。从2001年7月加入义隆直到2011年5月，他曾任义隆电子的财务总监。在加入义隆前，他曾任彭布罗克资本有限公司（航空租赁公司）的首席执行官，而在此之前，在一些银行和航空业担任金融高级职位。他是一名注册会计师。他目前是Prothena公司（一家公开上市的生物技术公司）和Onclave（一家私人持有的公司）的董事。
- Shane Cooke,served as President and as President of Alkermes Pharma Ireland Limited ("APIL"), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc ("Elan") and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. Mr. Cooke previously served on the board of directors of then publicly-traded healthcare companies UDG Healthcare plc from February 2019 to August 2021 and Endo International plc from July 2014 to April 2024. He is a chartered accountant.
高管简历
中英对照 | 中文 | 英文- David J. Gaffin
DavidJ.Gaffin高级副总裁，首席法律官。在担任现任职务之前，加芬先生于2014年1月至2016年5月担任Alkermes，Inc.美国总法律顾问Vice President。2011年10月至2014年1月，Gaffin先生担任Alkermes，Inc.副总法律顾问Vice President2009年10月至2011年10月，Mr.Gaffin曾任Alkermes，Inc.高级总监、副总法律顾问Gaffin先生于2005年加入Alkermes，Inc.，担任董事、副总法律顾问。在加入该公司之前，加芬先生曾在BiogenInc.担任助理总法律顾问，在那里他就产品相关事宜提供法律咨询，并就合作和许可交易进行谈判。
David J. Gaffin,served as Senior Vice President, Chief Legal Officer and Chief Compliance Officer of Alkermes, Inc. and Secretary of the Company from March 2018 to July 2022. Prior to that, Mr. Gaffin served as Senior Vice President and Chief Legal Officer of Alkermes, Inc. and Secretary of the Company from December 2017 to March 2018; Senior Vice President and Chief Legal Officer of Alkermes, Inc. from May 2016 to December 2017; Vice President, U.S. General Counsel of Alkermes, Inc., from January 2014 to May 2016; and Vice President, Deputy General Counsel of Alkermes, Inc. from October 2011 to January 2014; and prior to that in roles of increasing responsibility since joining Alkermes, Inc. in 2005. Prior to joining Alkermes, Mr. Gaffin held the role of Assistant General Counsel at Biogen Inc. ("Biogen"), a global biopharmaceutical company, where he provided legal counsel on product-related matters and collaboration and licensing transactions.- DavidJ.Gaffin高级副总裁，首席法律官。在担任现任职务之前，加芬先生于2014年1月至2016年5月担任Alkermes，Inc.美国总法律顾问Vice President。2011年10月至2014年1月，Gaffin先生担任Alkermes，Inc.副总法律顾问Vice President2009年10月至2011年10月，Mr.Gaffin曾任Alkermes，Inc.高级总监、副总法律顾问Gaffin先生于2005年加入Alkermes，Inc.，担任董事、副总法律顾问。在加入该公司之前，加芬先生曾在BiogenInc.担任助理总法律顾问，在那里他就产品相关事宜提供法律咨询，并就合作和许可交易进行谈判。
- David J. Gaffin,served as Senior Vice President, Chief Legal Officer and Chief Compliance Officer of Alkermes, Inc. and Secretary of the Company from March 2018 to July 2022. Prior to that, Mr. Gaffin served as Senior Vice President and Chief Legal Officer of Alkermes, Inc. and Secretary of the Company from December 2017 to March 2018; Senior Vice President and Chief Legal Officer of Alkermes, Inc. from May 2016 to December 2017; Vice President, U.S. General Counsel of Alkermes, Inc., from January 2014 to May 2016; and Vice President, Deputy General Counsel of Alkermes, Inc. from October 2011 to January 2014; and prior to that in roles of increasing responsibility since joining Alkermes, Inc. in 2005. Prior to joining Alkermes, Mr. Gaffin held the role of Assistant General Counsel at Biogen Inc. ("Biogen"), a global biopharmaceutical company, where he provided legal counsel on product-related matters and collaboration and licensing transactions.
- Joshua Reed
Joshua Reed，工商管理硕士，自2018年7月起担任我们的首席财务官。在加入Aldeyra之前，里德曾于2016年6月至2018年7月担任百时美施贵宝（Bristol-Myers Squibb’；s）美国和波多黎各业务的Vice President兼财务主管，2013年9月至2016年6月，该业务规模达120亿美元，里德曾担任执行董事，在此之前，Reed先生在BMS担任越来越重要的职务，包括财务规划和分析，供应链金融，运营金融以及并购方面的职位。在此之前，里德先生是摩根大通（JPMorgan Chase）负责战略业务发展的Vice President，并在瑞士信贷第一波士顿银行（Credit Suisse First Boston）担任投资银行职位，在那里他专注于并购。Reed先生在罗格斯大学（Rutgers University）获得金融学学士学位，并在密歇根大学罗斯商学院（University of Michigan&8217；s Ross School of Business）获得金融与企业战略方向的工商管理硕士学位。
Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business.- Joshua Reed，工商管理硕士，自2018年7月起担任我们的首席财务官。在加入Aldeyra之前，里德曾于2016年6月至2018年7月担任百时美施贵宝（Bristol-Myers Squibb’；s）美国和波多黎各业务的Vice President兼财务主管，2013年9月至2016年6月，该业务规模达120亿美元，里德曾担任执行董事，在此之前，Reed先生在BMS担任越来越重要的职务，包括财务规划和分析，供应链金融，运营金融以及并购方面的职位。在此之前，里德先生是摩根大通（JPMorgan Chase）负责战略业务发展的Vice President，并在瑞士信贷第一波士顿银行（Credit Suisse First Boston）担任投资银行职位，在那里他专注于并购。Reed先生在罗格斯大学（Rutgers University）获得金融学学士学位，并在密歇根大学罗斯商学院（University of Michigan&8217；s Ross School of Business）获得金融与企业战略方向的工商管理硕士学位。
- Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business.
- Craig C. Hopkinson
Craig C.Hopkinson，在担任当前职位之前，Hopkinson博士是我们的首席医疗官，以及Alkermes的药物开发和医疗事务高级副总裁，Inc.于2018年2月至2020年1月担任首席医疗官，并于2017年5月至2018年2月担任Alkermes, Inc.临床开发和医疗事务高级副总裁。在加入公司之前，Hopkinson博士于2014年7月至2017年5月担任全球生物制药公司Vertex Pharmaceuticals Incorporated的临床开发高级副总裁兼全球医疗事务主管。在此之前，Hopkinson博士在卫材制药担任过多个执行管理职位，包括从2013年1月到2014年7月担任卫材价值最大化系统总裁，从2011年10月到2012年12月担任Frontier Product Creation Unit的总裁兼首席医疗官。Hopkinson博士在研究与开发、医疗事务以及与FDA的互动方面拥有丰富的经验。
Craig C. Hopkinson,was Chief Medical Officer, and Senior Vice President of Medicines Development and Medical Affairs of Alkermes, Inc. from February 2018 to January 2020, and Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs of Alkermes, Inc. from May 2017 to February 2018. Prior to joining Alkermes, Dr. Hopkinson served as Senior Vice President of Clinical Development and Head of Global Medical Affairs at Vertex Pharmaceuticals Incorporated, a global biopharmaceutical company, from July 2014 until May 2017. Prior to that, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals, including President Eisai Value Maximization Systems from January 2013 to July 2014 and President and Chief Medical Officer of the Frontier Product Creation Unit from October 2011 to December 2012. Dr. Hopkinson has extensive experience in research and development, medical affairs, and interactions with the FDA. Dr. Hopkinson served on the board of directors of Albireo Pharma, Inc., a publicly-traded biopharmaceutical company, from December 2022 through its acquisition by Ipsen in March 2023.- Craig C.Hopkinson，在担任当前职位之前，Hopkinson博士是我们的首席医疗官，以及Alkermes的药物开发和医疗事务高级副总裁，Inc.于2018年2月至2020年1月担任首席医疗官，并于2017年5月至2018年2月担任Alkermes, Inc.临床开发和医疗事务高级副总裁。在加入公司之前，Hopkinson博士于2014年7月至2017年5月担任全球生物制药公司Vertex Pharmaceuticals Incorporated的临床开发高级副总裁兼全球医疗事务主管。在此之前，Hopkinson博士在卫材制药担任过多个执行管理职位，包括从2013年1月到2014年7月担任卫材价值最大化系统总裁，从2011年10月到2012年12月担任Frontier Product Creation Unit的总裁兼首席医疗官。Hopkinson博士在研究与开发、医疗事务以及与FDA的互动方面拥有丰富的经验。
- Craig C. Hopkinson,was Chief Medical Officer, and Senior Vice President of Medicines Development and Medical Affairs of Alkermes, Inc. from February 2018 to January 2020, and Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs of Alkermes, Inc. from May 2017 to February 2018. Prior to joining Alkermes, Dr. Hopkinson served as Senior Vice President of Clinical Development and Head of Global Medical Affairs at Vertex Pharmaceuticals Incorporated, a global biopharmaceutical company, from July 2014 until May 2017. Prior to that, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals, including President Eisai Value Maximization Systems from January 2013 to July 2014 and President and Chief Medical Officer of the Frontier Product Creation Unit from October 2011 to December 2012. Dr. Hopkinson has extensive experience in research and development, medical affairs, and interactions with the FDA. Dr. Hopkinson served on the board of directors of Albireo Pharma, Inc., a publicly-traded biopharmaceutical company, from December 2022 through its acquisition by Ipsen in March 2023.
- Blair C. Jackson
Blair C.Jackson，在担任现职之前，Jackson先生于2018年7月至2021年1月担任Alkermes, Inc.企业规划高级副总裁，负责我们的业务开发和联盟管理，业务规划，新产品规划，数据分析和市场研究以及企业运营职能。从2016年5月至2018年7月，杰克逊先生担任Alkermes, Inc.业务发展高级副总裁从2006年到2016年5月，Jackson先生担任Alkermes, Inc.业务发展副总裁。在此之前，自1999年加入公司以来，Jackson先生在Alkermes, Inc.担任过各种科学和公司职务。Jackson先生是Synchronicity Pharma，Inc.（一家私人临床阶段生物制药公司）的董事会成员。
Blair C. Jackson,served as Executive Vice President, Chief Operating Officer from January 2021 to April 2024. Prior to that, Mr. Jackson served as Senior Vice President, Corporate Planning of Alkermes, Inc. from July 2018 to January 2021, responsible for Alkermes Public Limited Company business development and alliance management, business planning, new product planning, data analytics and market research and corporate operations functions. From May 2016 to July 2018, Mr. Jackson served as Senior Vice President, Business Development of Alkermes, Inc. From 2006 to May 2016, Mr. Jackson served as Vice President, Business Development of Alkermes, Inc. Prior to that, Mr. Jackson held various scientific and corporate roles within Alkermes, Inc. since joining Alkermes in 1999. Mr. Jackson is a member of the board of directors of Synchronicity Pharma, Inc., a private clinical-stage biopharmaceutical company.- Blair C.Jackson，在担任现职之前，Jackson先生于2018年7月至2021年1月担任Alkermes, Inc.企业规划高级副总裁，负责我们的业务开发和联盟管理，业务规划，新产品规划，数据分析和市场研究以及企业运营职能。从2016年5月至2018年7月，杰克逊先生担任Alkermes, Inc.业务发展高级副总裁从2006年到2016年5月，Jackson先生担任Alkermes, Inc.业务发展副总裁。在此之前，自1999年加入公司以来，Jackson先生在Alkermes, Inc.担任过各种科学和公司职务。Jackson先生是Synchronicity Pharma，Inc.（一家私人临床阶段生物制药公司）的董事会成员。
- Blair C. Jackson,served as Executive Vice President, Chief Operating Officer from January 2021 to April 2024. Prior to that, Mr. Jackson served as Senior Vice President, Corporate Planning of Alkermes, Inc. from July 2018 to January 2021, responsible for Alkermes Public Limited Company business development and alliance management, business planning, new product planning, data analytics and market research and corporate operations functions. From May 2016 to July 2018, Mr. Jackson served as Senior Vice President, Business Development of Alkermes, Inc. From 2006 to May 2016, Mr. Jackson served as Vice President, Business Development of Alkermes, Inc. Prior to that, Mr. Jackson held various scientific and corporate roles within Alkermes, Inc. since joining Alkermes in 1999. Mr. Jackson is a member of the board of directors of Synchronicity Pharma, Inc., a private clinical-stage biopharmaceutical company.
- C. Todd Nichols
C.Todd Nichols先生在担任现职之前，于2019年5月至2020年5月担任Alkermes, Inc.高级副总裁兼销售与市场营销。在加入Alkermes, Inc.之前，尼科尔斯先生于2018年至2019年担任全球生物制药公司新基医药公司的销售与市场营销，炎症和免疫学副总裁，并担任全球生物制药公司Biogen，Inc.的销售和现场运营，神经学和血友病副总裁，从2014年到2017年。在此之前，Nichols先生在默克制药公司“；Merck”；工作，从2011年到2014年担任美国疫苗业务单元的副总裁兼负责人，从2009年到2011年担任专业商业运营-妇女’；保健的全国销售负责人。在此之前，Nichols先生在2009年被Merck收购的Schering-Plough Corporation担任过多个职位，包括地区副总裁，销售和区域销售总监。
C. Todd Nichols,served as Senior Vice President, Sales and Marketing of Alkermes, Inc. from May 2019 to May 2020. Prior to joining Alkermes, Inc., Mr. Nichols served as Vice President of Sales and Marketing, Inflammation and Immunology at Celgene Corporation, a global biopharmaceutical company, from 2018 to 2019 and as Vice President of Sales and Field Operations, Neurology and Hemophilia at Biogen from 2014 to 2017. Prior to that, Mr. Nichols worked for Merck, serving as Vice President and Head of the US Vaccines Business Unit from 2011 to 2014 and as National Sales Leader, Specialty Commercial Operations-Women's Health Care from 2009 to 2011. Prior to that, Mr. Nichols held a variety of positions at Schering-Plough Corporation (acquired by Merck in 2009), including Area Vice President, Sales and Regional Sales Director.- C.Todd Nichols先生在担任现职之前，于2019年5月至2020年5月担任Alkermes, Inc.高级副总裁兼销售与市场营销。在加入Alkermes, Inc.之前，尼科尔斯先生于2018年至2019年担任全球生物制药公司新基医药公司的销售与市场营销，炎症和免疫学副总裁，并担任全球生物制药公司Biogen，Inc.的销售和现场运营，神经学和血友病副总裁，从2014年到2017年。在此之前，Nichols先生在默克制药公司“；Merck”；工作，从2011年到2014年担任美国疫苗业务单元的副总裁兼负责人，从2009年到2011年担任专业商业运营-妇女’；保健的全国销售负责人。在此之前，Nichols先生在2009年被Merck收购的Schering-Plough Corporation担任过多个职位，包括地区副总裁，销售和区域销售总监。
- C. Todd Nichols,served as Senior Vice President, Sales and Marketing of Alkermes, Inc. from May 2019 to May 2020. Prior to joining Alkermes, Inc., Mr. Nichols served as Vice President of Sales and Marketing, Inflammation and Immunology at Celgene Corporation, a global biopharmaceutical company, from 2018 to 2019 and as Vice President of Sales and Field Operations, Neurology and Hemophilia at Biogen from 2014 to 2017. Prior to that, Mr. Nichols worked for Merck, serving as Vice President and Head of the US Vaccines Business Unit from 2011 to 2014 and as National Sales Leader, Specialty Commercial Operations-Women's Health Care from 2009 to 2011. Prior to that, Mr. Nichols held a variety of positions at Schering-Plough Corporation (acquired by Merck in 2009), including Area Vice President, Sales and Regional Sales Director.
- Richard F. Pops
Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012.- Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
- Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012.